Unlike peers, GSK plc faces limited Loss of Exclusivity risk, supporting steady revenue projections and justifying higher ...

GSK plc’s strong oncology growth, highlighted by Ojjaara sales and an upgraded 2025 outlook, earns a continued 'Buy' rating.

Part of a pharmaceutical factory which opened more than 75 years ago will be demolished. GSK plc (formerly GlaxoSmithKline) ...

GSK (LSE:GSK) shares have delivered a solid run recently, gaining 9% over the past month and 14% in the past 3 months. Investors are keeping an eye on what is driving this positive momentum and how ...

ANTWERPEN, BE / ACCESS Newswire / October 9, 2025 /OMP, a leader in supply chain planning solutions, is spotlighting at the ...

GSK plc (LSE/NYSE: GSK) has unveiled a major update to its Vaccine Track platform, expanding the interactive public data tool to include vaccination trends across 387 U.S.

GSK Chief Executive Emma Walmsley, the first woman to lead a major pharmaceutical company, will step down Dec. 31 after more ...

In the latest trading session, GSK (GSK) closed at $34.78, marking a -0.83% move from the previous day. This change was narrower than the S&P 500's daily loss of 1.2%. Elsewhere, the Dow lost 1.1%, ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...

In the latest trading session, GSK (GSK) closed at $35.30, marking a +0.89% move from the previous day. This change lagged the S&P 500's 1.49% gain on the day. Elsewhere, the Dow gained 1.6%, while ...

GSK has announced a $30bn investment in the US over the next five years in research and development (R&D) and supply chain.